It will experience more deterioration....Too many unknowns .I like tthe company and will acquire more slowly
If you worry about what WallStreet thinks then you are gambling not investing.
WHile buybacks are good for short/medium term, GILD needs a strategy. Until then GILD is a buying opportunity.
billybob...I would be embarrassed to publish that name......I bought 10 shares of BRK for $5K in 1988....
He can keep the dividends...LOL...Why would I want to pay tax every year when he reinvested the money at a greater return than I could get by myself....Say sooooheeeee. billybob.....
The following was written be a very credible biotech, ex-doctor analyst who provides detailed analysis of biotech pipelines. The AUTHOR id also a holder of IONS for the long-term. This quote is an excerpt from a detailed article written in March 2016.
"This is a highly risky stock. If there is one more major disappointment soon, the Street may resume its highly skeptical view of the company and the stock that it maintained most of the time from 1992 onward for about 2 decades. Genzyme has given up on Kynamro, a material negative given high hopes for a degree of real success for this drug.
The stock is very volatile with no obvious fundamental support at any special price level."
You have no idea about the patent portfolio with GILD. They continue to advance the HCV product line and we will see a pan-Geno HCV treatment soon that will have long patent protection. Quit misrepresenting the HCV product and pipeline.
For those who want to understand the pipleline I suggest reading articles written by DoctoRx on Seeking Alpha.
Sentiment: Strong Buy
The HIV market is strong for GILD and growing. GILD miss on revenue was caused by several factors, all reasonable. Additionally, the $200M for Merck lawsuit added a one-time decrease to EPS.
However, it is quite likely that the verdict will be overturned by judge. Additionally, MERCK patent attorney lied so GILD will probably go after MERCK for patent infringement. Merck will end up being small competitor in HCV or most definitely will be paying GILD royalties for using confidential information gained from its discussions with Pharmasett when filing its patents.
GILD GM is now 86%.
IONS will see huge selling pressure. Revenue was only $38M for qtr. The market is punishing biotech for the time being. The pipeline is great as well as the partnerships, but that will not stop IONS from being punished. I would not be surprised to see the PPS go into the 20s.
I am waiting for a compelling price to buy more.
Only the partnerships and a potential buyout will protect the stock price from going too low.
Long term should be great company, but the revenue stream is years away.
I expect the judge to set aside the jury verdict. I also expect GILD to file suit against Merck for patent infringement since Durette has "unclean hands." IONS will see no money from GILD.
PTLA is going down wit the rest of biotech. The volume is low so there is no significant movement by large institutions. This is program trading at low volume. HOLD
BRCD is resting on SAN business and repositioning to go after service providers. The SP business is weak. BRCD has much to do to take SP business from CSCO and Juniper. The SAN (cash cow) business will start to erode soon.
What is your point? Do you understand the earnings and revenue and why they fell the way they did? The market will be buying GILD next week, because no the bad news came out.
They just promoted the CEO into the position and this was his first conference call where he was solely responsible. GILD makes money and is moving at a speed that works for the business.
If you bought the stock as an INVESTOR not trader in the 40s why do you care about a short term abberation?
At 10PE on $12 expected earnings the stock is $120. However, the company needs to fix the story.
even at 8 PE the stock is $96.
Crude price has no short term influence on AWLCF. The WillPhoenix completed yard stay so Awilco told Apache "we want to e paid standby rate." Apache says the ship did not complete the yard work to their satisfaction, i.e. Apache is trying to get out of the contract or delay cash flow as much as possible. Bottom line, no cash coming in so no divy should be expected. The Good News is the yard work was completed at lower cost than budgeted.
I'm also quite sure the CFO provided "private" guidance to the major IBs, something they have not done in the past. Why would the stock go up so much prior to earnings? Short covering may be part of it, but I am not sure.